Sun pharma geared up to introduce Molnupiravir to treat covid infected adults in India

0 27

Sun Pharma, on Thursday, announced that they are coming up with a new medicine for the treatment of COVID-19 infected adults in India. The company, through a press release, cleared that it is gearing up to introduce Merck Sharpe Dohme (MSD) and Ridgeback’s molnupiravir, under the brand name Molxvir® in India. 

The firm, earlier this year, had signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply molnupiravir to over 100 low and middle-income countries and in India. The drug has been going through the review phase by the Drugs Controller General of India (DCGI).

“The recent authorisation of molnupiravir, licensed from MSD and Ridgeback, by the UK regulator is a positive step. In line with our consistent efforts to accelerate access to new drugs for COVID-19 treatment, we are gearing up to make Molxvir® available to patients and healthcare providers across India at an economical price post approval by DCGI. Molxvir® will be manufactured at one of our plants in India and we have enough capacity to meet the demand.”

Kirti Ganorkar, CEO of India Business, Sun Pharma

Molnupiravir is the first oral antiviral that got approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to treat mild-to-moderate COVID -19 infected adults. The U.S. Food and Drug Administration (FDA) is alsMolnupiraviro reviewing the drug for Emergency Use Authorisation (EUA). 

In the Phase 3 trial by Merck, Molnupiravir significantly reduced the risk of hospitalization or death by approximately 50% in non-hospitalized adult patients with mild-to-moderate COVID-19.

See the Tweet here:

Leave A Reply

Your email address will not be published.